Country-wide medical records infer increased allergy risk of gastric acid inhibition

Galateja Jordakieva, Michael Kundi, Eva Untersmayr, Isabella Pali-Schöll, Berthold Reichardt & Erika Jensen-Jarolim 

Nature Communications volume 10, Article number: 3298 (2019) | Download Citation

Abstract

Gastric acid suppression promotes allergy in mechanistic animal experiments and observational human studies, but whether gastric acid inhibitors increase allergy incidence at a population level remains uncharacterized. Here we aim to assess the use of anti-allergic medication following prescription of gastric acid inhibitors. We analyze data from health insurance records covering 97% of Austrian population between 2009 and 2013 on prescriptions of gastric acid inhibitors, anti-allergic drugs, or other commonly prescribed (lipid-modifying and antihypertensive) drugs as controls.

Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults

Wendy Lim    Waqqas Afif    Sandra Knowles    Gloria Lim    Yulia Lin    Charmaine Mothersill    Irina Nistor  Faisal Rehman    Christine Song    Ted Xenodemetropoulos

Original Paper  Open Access

Abstract
Background and Objectives
Rare but potentially life‐threatening hypersensitivity reactions can occur during the administration of intravenous iron. To provide guidance to healthcare professionals caring for adults receiving intravenous iron, a panel of 10 Canadian clinical experts developed a practical algorithm for the identification and management of hypersensitivity reactions to intravenous iron.

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA

Respiratory Research
• Research
• OPEN
• 
  

• Frank C. Albers, 
• Alberto Papi, 
• Camille Taillé, 
• Daniel J. Bratton, 
• Eric S. Bradford, 
• Steven W. Yancey & 
• Namhee Kwon 

Respiratory Researchvolume 20, Article number: 169 (2019) | Download Citation

Abstract

Ratio of the annual rate of clinically significant exacerbations.
Mepolizumab 100 mg SC versus placebo. CI confidence interval, SC subcutaneous

Background

We assessed the efficacy of the licensed mepolizumab dose (100 mg subcutaneously [SC]) in patients with severe eosinophilic asthma according to body weight/body mass index (BMI).

IgE level in newborn umbilical cord and its relationship with some maternal factors

Clinical and Molecular Allergy 
• Research
• OPEN
• 
  

• Iraj Mohammadzadeh, 
• Mohsen Haghshenas, 
• Samaneh Asefi & 
• Reza Alizadeh-Navaei 

Clinical and Molecular Allergyvolume 17, Article number: 11 (2019) |

Abstract

Background and objectives

Allergic diseases are among major pediatric issues as they are highly prevalent and chronic. Therefore, identification of factors contributing to allergic disease could play a significant role in prevention of these conditions. This study aimed at investigating the IgE level in newborn’s umbilical cord blood and its relationship with some maternal factors.

Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics

Allergo J Int (2019). https://doi.org/10.1007/s40629-019-0100-8

Open Access 

guidelines

Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Society of Allergology (AeDA), German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Austrian Society for Allergology and Immunology (ÖGAI), and the Paul-Ehrlich Society for Chemotherapy (PEG)

• Gerda Wurpts
• Werner Aberer 
• Heinrich Dickel 
• Randolf Brehler 
• Thilo Jakob 
• Burkhard Kreft 
• Vera Mahler
• Hans F. Merk 
• Norbert Mülleneisen 
• Hagen Ott 
• Wolfgang Pfützner 
• Stefani Röseler 
• Franziska Ruëff
• Helmut Sitter 
• Cord Sunderkötter 
• Axel Trautmann 
• Regina Treudler 
• Bettina Wedi 
• Margitta Worm
• Knut Brockow

Abstract

This guideline on diagnostic procedures for suspected beta-lactam antibiotic (BLA) hypersensitivity was written by the German and Austrian professional associations for allergology, and the Paul-Ehrlich Society for Chemotherapy in a consensus procedure according to the criteria of the German Association of Scientific Medical Societies.

Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm

Clinical and Translational Allergy
 
• Review
• OPEN

• Polliana Mihaela Leru 

Clinical and Translational Allergyvolume 9, Article number: 36 (2019) | Download Citation

Abstract

A proposed diagnostic algorithm of Hypereosinophilia and Eosinophilic diseases

Eosinophilic disorders represent a group of pathologic conditions with highly heterogeneous pathophysiology and clinical presentation and variable prognosis, ranging from asymptomatic or mild, to severe and complex cases, with fatal outcome. Interest in this group of disorders has increased during the last two decades, with consistent progress made regarding understanding of molecular mechanisms, refining of diagnostic criteria, classification and evaluation of therapeutic options. There are still many gaps and difficulties in evaluating eosinophilic syndromes and diseases in medical practice.

Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma

• Technical advance
• OPEN Open Peer Review
• 
  

BMC Pulmonary Medicine

Mattis Gottlow, 

David J. Svensson, 

Ilya Lipkovich, 

Monika Huhn, 

Karin Bowen, 

Peter Wessman & 

Gene Colice 

BMC Pulmonary Medicinevolume 19, Article number: 129 (2019) | Download Citation

Abstract

Background

Staggered trial design of STRATOS 1 and 2. Q2W,
every 2 weeks; Q4W, every 4 weeks; SC, subcutaneous

Tralokinumab is an anti–interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2. The STRATOS 1 biomarker analysis plan was developed to identify biomarker(s) indicative of IL-13 activation likely to predict tralokinumab efficacy and define a population in which there was an enhanced treatment effect; this defined population was then tested in STRATOS 2.

Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study

• Research
• OPEN
• Clinical and Translational Allergy

• Bastsetseg Ulambayar, 
• Eun-Mi Yang, 
• Hyun-Young Cha, 
• Yoo-Seob Shin, 
• Hae-Sim Park & 
• Young-Min Ye 

Clinical and Translational Allergyvolume 9, Article number: 33 (2019) | Download Citation

Abstract

Background

Platelet activating factor (PAF) is an endogenous, active phospholipid released from inflammatory cells, platelets, and endothelial cells, and is involved in the regulation of immune responses. Degradation of PAF by PAF acetylhydrolase (PAF-AH) has been shown to be associated with anaphylaxis, asthma, and peanut allergy.

Serum levels of PAF (a) and PAF-AH (b) and PAF-AH to PAF ratio (c)
in patients with CSU and NCs. PAF platelet activating factor, PAF-AH platelet activating factor acetylhydrolase, CSU chronic spontaneous urticaria, NC healthy normal control. p values
were calculated by Mann–Whitney U-test

The purpose of this study was to investigate relationships among clinical parameters, including urticaria severity and treatment responsiveness, and PAF and PAF-AH levels in sera from patients with chronic spontaneous urticaria (CSU).